Pentoxifylline and leukocyte function

Cover of: Pentoxifylline and leukocyte function |

Published by Hoechst-Roussel Pharmaceuticals in Somerville, N.J .

Written in English

Read online

Subjects:

  • Pentoxifylline -- Physiological effect -- Congresses.,
  • Neutrophils -- Congresses.,
  • Inflammation -- Congresses.,
  • Pentoxifylline -- Testing -- Congresses.

Edition Notes

Book details

Statementco-editors, Gerald L. Mandell, William J. Novick, Jr.
ContributionsMandell, Gerald L., Novick, William J.
Classifications
LC ClassificationsRM666.P375 P46 1988
The Physical Object
Paginationv, 253 p. :
Number of Pages253
ID Numbers
Open LibraryOL2277489M
LC Control Number89168367

Download Pentoxifylline and leukocyte function

PENTOXIFYLLINE AND LEUKOCYTE FUNCTION Proceedings of a Symposium Held in Key Biscayne, Florida 30 November - 1 December [Mandell, Gerald L. & William J. Novick, Jr.] on *FREE* shipping on qualifying offers.

PENTOXIFYLLINE AND LEUKOCYTE FUNCTION Proceedings of a Symposium Held in Key Biscayne, Florida 30 November - 1 December Author: Jr. Mandell, Gerald L. & William J. Novick. Pentoxifylline and Leukocyte Function Paperback – January 1, by W J Mandell, G L & Novick (Author) See all formats and editions Hide other formats and editions.

Price New from Used from Paperback, January 1, "Please retry" $ — $ Paperback $ 2 Used Author: W J Mandell, G L & Novick. Pentoxifylline and Analogues: Effects on Leukocyte Function: Workshop, Saint Paul-de-Vence, November Proceedings: Medicine & Health Science Books @.

Pentoxifylline and Analogues: Effects on Leukocyte Function: Workshop, Saint Paul-de-Vence, November Proceedings by Hakim, J. and a great selection of related books, art and collectibles available now at In summary, pentoxifylline appears to be an interesting immunomodulator (ie, immunoenhancement and immunosuppression) of leukocyte function in vitro, but additional studies will be required before.

At extremely low concentrations ( mg/ml), pentoxifylline enhanced oxygen metabolism by human leukocytes, as reflected by increased H2O2 production and chemiluminescence (CL).

At higher concentrations (ie, to 1 mg/ml), pentoxifylline consistently suppressed these leukocyte functions in. Pentoxifylline suppresses TNF-α gene transcription, potentiates the expression of inducible nitric oxide (NO) synthetase leading to NO production and decreases leukocyte migration and adhesion.[42,43] TNF-α seems to play a great role in the pathogenesis of mucosal leishmaniasis[42,43,44] and pentoxifylline has been proposed for the treatment.

Pentoxifylline (PTX), a methylxanthine derivative widely used for the symptomatic treatment of various vascular disorders, was recently found to have anti-inflammatory effects. PTX can suppress tumor necrosis factor-α production and function, and inhibits leukocyte-endothelial cell.

Abstract. Impaired mononuclear leucocyte (MNL) motility can be found both in vascular and autoimmune diseases. Pentoxifylline (PTX) has a well-known therapeutic effect in vascular diseases, which is based on the rearrangement of blood cell cytoskeleton and thus increased microcirculatory flow.

Pentoxifylline improves the rheological properties of blood in multiple ways. Pentoxifylline is a methylxanthine derivative used for the past three decades to treat intermittent claudication.

1–3 In clinical doses—typically mg three times daily—it improves the rheological properties of blood in numerous ways: decreasing plasma and whole blood viscosity, in large measure.

Pentoxifylline modulation of plasma membrane functions in human polymorphonuclear leukocytes. Infect Immun. Nov; 57 (11)– [PMC free article] Ishizaka A, Hatherill JR, Harada H, Yonemaru M, Hoffmann H, Zheng H, O'Hanley PT, Raffin TA. Prevention of interleukin 2-induced acute lung injury in guinea pigs by pentoxifylline.

We have previously shown that pentoxifylline, a drug used in intermittent claudication, causes depolymerization of actin in leukocytes in vitro. In this study we evaluated several parameters in peripheral blood obtained from 17 patients receiving pentoxifylline, before therapy and at 1 and 2 months after initiation of drug therapy.

Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. Rao KM(1), Simel DL, Cohen HJ, Crawford J, Currie MS. Author information: (1)Geriatric Research, Education, and Clinical Center, Veterans Administration Medical Center, Durham, NC Barroso-Aranda J, Schmid-Schonbein G () Pentoxifylline pretreatment decreases neutrophil activation during endotoxic shock and improves survival.

In: Hakim J, Mandell GL, Novick WJ (eds) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 97– Google Scholar.

Journals & Books; Help Pentoxifylline and Leukocyte Function () Key Biscayne Florida Boogaerts, M.A. Malbrain, S. Meeus, P. Van Hove, L. Vernhoef, G.E.G.

In vitro modulation of normal and diseased neutrophil function by pentoxifylline Blut () The nucleoside adenosine (ADO) has been shown to inhibit several leukocyte functions, such as the production of superoxide anions, degranulation, adherence, and cell-mediated cytotoxicity, and can.

The fibrinogen decrease observed with Pentoxifylline is within the magnitude of difference in epidemiological studies that is associated between vascular death and comparative groups (In the Goteborg prospective study (5), fibrinogen level had been g/1 and g/1 in patients with further myocardial infarction and stroke respectively.

Pentoxifylline increases blood flow to the affected microcirculation. Although the precise mechanism of action is not well-defined, blood viscosity is lowered, erythrocyte flexibility is increased, leukocyte deformability is increased, and neutrophil adhesion and activation are decreased.

Overall, tissue oxygenation is significantly increased. Pentoxifylline is known to have major effects on cell membrane function in mammalian cells, including human leukocytes. The protective effects of this agent in animal models of infection and inflammation may be due to alterations in phagocyte (neutrophil and macrophage) function.

However, the exact mechanism of action of pentoxifylline is unknown. Pentoxifylline has a broad range of effects and was, therefore, unlikely to provide complete treatment for long-standing radiation-induced fibrosis. Indeed, as may have been anticipated, the response to pentoxifylline was not consistent, which could be the result of long standing fibrosis and potential irreversibility in some of the patients.

Appearance, Color, and Odor. Pentoxifylline is a white, or almost white, crystalline or microcrystalline powder, which has a bitter taste and only a slight characteristic odor [2, 5].

Uses and applications. Pentoxifylline decreases the viscosity of blood, and thereby improves its flow. This increased blood flow helps patients with peripheral arterial disease to obtain better.

Pentoxifylline and Analogues: Effects on Leukocyte Function Workshop, Saint Paul-de-Vence, November Proceedings Editor(s): Hakim, J.

(Paris). Pharmac. 8, Schmalzer E. and Chien S. () Filterability of subpopulations of leukocytes: effect of pentoxifylline.

Bl Stefanovich V. () Effect of 3,7-dimethyl-1(5-oxo-hexyl) xanthine and 1-hexyl-3,7-dimethyl xanthine on cyclic-AMP phosphodiesterase of the human umbilical cord vessels. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility.

Leukocyte properties of hemorrheologic importance have been modified in animal and in vitro human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit.

In patients with severely impaired liver function the dosage may need to be reduced. In patients treated concomitantly with pentoxifylline and anti-vitamin K or platelet aggregation inhibitors (see also section ).

In patients treated concomitantly with pentoxifylline and antidiabetic agents (see also section ). Knox P () Leukocyte-mediated activation of the fibrinolytic pathway and the effects of pentoxifylline. In: Mandell GL, Novick WJ Jr (eds) Pentoxifylline and leukocyte function.

Proc Pentoxifylline Symposium, Key Biscayne. Hoechst-Roussel Pharmaceuticals, Somerville, p 96. pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility.

Leukocyte properties of hemorrheologic importance have been modified in animal and. in vitro. (pentoxifylline) Tablets, mg Leukocyte properties of hemorrheologic importance have been modified in animal and.

in vitro. human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil function, and of concomitant disease or other drug therapy. The purpose of this study was to determine if pentoxifylline (PTX) would reduce leukocyte trapping in postischemic hearts.

Isolated rat hearts were subjected to 30 min of 37°C, no-flow ischemia. Hearts were initially reperfused with diluted whole blood containing fluorescent leukocytes. Pentoxifylline Reduces Coronary Leukocyte Accumulation Early in Reperfusion After Cold Ischemia Stephen C. Gale, MD, Jason Y.

Hokama, PhD, Leslie S. Ritter, PhD, Preserving endothelial function dur-ing ischemia may limit leukocyte accumulation and. INDICATIONS. Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs.

Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular.

The proliferation rate of the cells treated with 1 mM Pentoxifylline (PTX) significantly decreased compared with that of the control in T6 cells ( ± % at 12 h, ± % at 24 h, and ± % at 48 h, p. PTX (1 mM) also decreased the fraction of the hepatic stellate cells (HSC) population in the S and G2/M-phases of the cell cycle in primary activated rat HSCs.

Pentoxifylline improves the rheological properties of blood in multiple ways. Pentoxifylline is a methylxanthine derivative used for the past three decades to treat intermittent claudication.1–3 In clinical doses—typically mg three times daily—it improves the rheological properties of blood in numerous ways: decreasing plasma and whole blood viscosity, in large measure.

Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Leukocyte properties of hemorrheologic importance have been modified in animal and in vitro human studies.

Pentoxifylline has been shown to increase leukocyte deformability and to inhibit. Pentoxifylline (PTX) has been shown to combat effectively endotoxin induced symptoms of shock or inflammation by reducing both leukocyte activation and endogenous cytokine formation. With regard to blood perfusion, inflammation is defined as a local reaction to injury of the living microvasculature and its content.

Leukocyte margination, rolling, adhesion, and emigration is mediated by. The leukocyte, commonly known as a white blood cell (or WBC), is a major component of the body’s defenses against ytes protect the body against invading microorganisms and body cells with mutated DNA, and they clean up debris.

Platelets are essential for the repair of blood vessels when damage to them has occurred; they also provide growth factors for healing and repair. Cardiothoracic Transplantation Pentoxifylline is as effective as leukocyte depletion for modulating pulmonary reperfusion injury Stephen C.

Clark, FRCS(C/Th)a Jagan N. Rao, FRCSa Paul A. Flecknell, MRCVSb John H. Dark, FRCSa Objective: Previous studies have suggested the amelioration of lung reperfusion injury when initial reperfusion is undertaken with leukocyte-depleted blood. pentoxifylline groups. and pentoxifylline-exposed PMNhad equalized.

Thus, the rate of S. aureus phagocytosis by pentoxifylline-exposed PMNwasslower,butthetotal numberofingestedorganisms was the same as with control cells. It is of interest that pentoxifylline at a low concentration of ' Mactually appearedto stimulate ingestionofS.

aureusat 5. About this Item: Plenum Publishing Corporation, Hardcover. Condition: Good. Hardback with dustjacket - - condition, slight spine lean, dj is a bit rough - - used books, secondhand books, for sale, out of print books, hard to find books, second-hand books, college books, student books, nonfiction, first editions, exlibrary books sold, non-fiction books delivered world wide.

Pentoxifylline has also been shown to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit production of the cytokine, tumor necrosis factor-alpha (TNF).

Pentoxifylline is indicated in the treatment of intermittent claudication associated with peripheral vascular diseases (i.e., chronic occlusive arterial.

Pentoxifylline has multiple effects on leukocyte function, including reducing leukocyte adhesion, [27,28 ] reducing degranulation, [15,29 ] reducing superoxide production by leukocytes, [15–28 ] and reducing TNF-alpha production by macrophages. Pentoxifylline is a tri-substituted xanthine derivative designated chemically as 3,7-Dihydro-3,7-dimethyl(5-oxohexyl)-1H-purine-2,6-dione that, unlike theophylline, is a hemorrheologic agent, i.e., an agent that affects blood viscosity.

Pentoxifylline is soluble in water and ethanol, and sparingly soluble in toluene.Pentoxifylline also significantly decreased lactate and protein concentrations (P less than ) and tended to diminish leukocyte counts (P = ) compared with results in control animals after.

83439 views Monday, November 23, 2020